title: Antibodies to watch in 2010.
abstract: Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed to regulatory approval or been approved. Of particular interest are the 26 mAbs that are currently at Phase 3, when safety and efficacy data critical to approval is established. Phase 3 study lengths are typically two to four years, so results for some studies might be announced in 2010, but data from others might not be presented until 2014. This overview of the 26 candidates provides a brief description of the background and the on-going Phase 3 studies of each mAb. Additional mAbs that have progressed to regulatory review or been approved may also be in Phase 3 studies, but these, as well as Fc fusion proteins, have been excluded. Due to the large body of primary literature about the 26 candidates, only selected references are given, with a focus on recent publications and articles that were relevant to Phase 3 studies. Current as of October 2009, the results presented here will serve as a baseline against which future progress can be measured.
authors.affiliation: Tufts Center for the Study of Drug Development, Boston, MA, USA. janice.reichert@tufts.edu
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000276:immunology; D017277:Drug Approval; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D016023:Integrins / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D017978:Receptors, Growth Factor / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D016207:Cytokines; D016023:Integrins; D017978:Receptors, Growth Factor